Follow up Study of Patients Having Participated in Clinical Trial 64,185-204
Status:
Completed
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
The objectives of this follow up study are to evaluate the long-term effects of stannsoporfin
(Stanate) on the health, growth, and development of patients who received a single dose of
stannsoporfin with PT used to treat hyperbilirubinemia compared with patients in the control
(placebo plus PT) group in clinical trial 64,185-204.
Details
Lead Sponsor:
InfaCare Pharmaceuticals Corporation InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company